Clinical Trial Update: A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients [Phase 1]

View source ↗

Summary

This document announces the completion of a first-in-human Phase 1 study of IBI356 in healthy participants and in patients with atopic dermatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• IBI356

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Healthy Participants, Atopic Dermatitis Patients | Phase 1 | Status: COMPLETED